应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06821 凯莱英
交易中 12-19 11:10:07
76.900
+4.450
+6.14%
最高
77.000
最低
72.700
成交量
16.19万
今开
72.700
昨收
72.450
日振幅
5.94%
总市值
277.61亿
流通市值
21.19亿
总股本
3.61亿
成交额
1,225万
换手率
0.59%
流通股本
2,755万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
医药外包概念普遍走高 药明生物(02269)涨6.11% 机构看好看好CXO在业绩和估值端迎来双重修复
金吾财讯 · 44分钟前
医药外包概念普遍走高 药明生物(02269)涨6.11% 机构看好看好CXO在业绩和估值端迎来双重修复
每日卖空追踪 | 凯莱英 12月17日卖空量成交1200股,卖空比例为0.58%
市场透视 · 12-17 16:30
每日卖空追踪 | 凯莱英 12月17日卖空量成交1200股,卖空比例为0.58%
每日卖空追踪 | 凯莱英 12月15日卖空量成交1900股,卖空比例为1.24%
市场透视 · 12-15
每日卖空追踪 | 凯莱英 12月15日卖空量成交1900股,卖空比例为1.24%
医药行业周报:IN VIVO CART:BD热门赛道 早期技术具备广阔前景
中信建投证券 · 12-14
医药行业周报:IN VIVO CART:BD热门赛道 早期技术具备广阔前景
英伟达连续布局13家企业,AI制药3个方向梳理(附列表)
投研大叔 · 12-13
英伟达连续布局13家企业,AI制药3个方向梳理(附列表)
每日卖空追踪 | 凯莱英 12月12日卖空量成交3800股,卖空比例为1.5%
市场透视 · 12-12
每日卖空追踪 | 凯莱英 12月12日卖空量成交3800股,卖空比例为1.5%
诺华领跑,药明康德狂飙!小核酸药物市场井喷,中国CDMO产业链迎来爆发式增长
摩熵医药 · 12-11
诺华领跑,药明康德狂飙!小核酸药物市场井喷,中国CDMO产业链迎来爆发式增长
重磅事件落地!商业化+出海提速,板块调整后弹性更突出
浙商证券融资融券 · 12-10
重磅事件落地!商业化+出海提速,板块调整后弹性更突出
每日卖空追踪 | 凯莱英 12月09日卖空量成交6900股,卖空比例为2.8%
市场透视 · 12-09
每日卖空追踪 | 凯莱英 12月09日卖空量成交6900股,卖空比例为2.8%
ADC药物浪潮下,凯莱英、药明合联等CDMO企业产能角逐正酣
制药网 · 12-08
ADC药物浪潮下,凯莱英、药明合联等CDMO企业产能角逐正酣
每日卖空追踪 | 凯莱英 12月08日卖空量成交1.13万股,卖空比例为2.97%
市场透视 · 12-08
每日卖空追踪 | 凯莱英 12月08日卖空量成交1.13万股,卖空比例为2.97%
凯莱英12月08日主力净流入488.6万元 散户资金抛售
市场透视 · 12-08
凯莱英12月08日主力净流入488.6万元 散户资金抛售
港股异动 | 凯莱英(06821)午前涨近3% 近期凯莱英生物上海奉贤基地正式投产 重点布局联药物NDCs等领域
智通财经 · 12-08
港股异动 | 凯莱英(06821)午前涨近3% 近期凯莱英生物上海奉贤基地正式投产 重点布局联药物NDCs等领域
每日卖空追踪 | 凯莱英 12月04日卖空量成交300股,卖空比例为0.16%
市场透视 · 12-04
每日卖空追踪 | 凯莱英 12月04日卖空量成交300股,卖空比例为0.16%
凯莱英12月04日主力净流入71.1万元 散户资金抛售
市场透视 · 12-04
凯莱英12月04日主力净流入71.1万元 散户资金抛售
每日卖空追踪 | 凯莱英 12月03日卖空量成交1200股,卖空比例为1.66%
市场透视 · 12-03
每日卖空追踪 | 凯莱英 12月03日卖空量成交1200股,卖空比例为1.66%
凯莱英(002821)披露A股股权激励股份转让进展,12月2日股价下跌2.06%
证券之星 · 12-02
凯莱英(002821)披露A股股权激励股份转让进展,12月2日股价下跌2.06%
行业回暖!盘点2025年CXO订单最高的10家公司:药明系领跑,凯莱英、泰格医药等巨头订单激增
摩熵医药 · 12-02
行业回暖!盘点2025年CXO订单最高的10家公司:药明系领跑,凯莱英、泰格医药等巨头订单激增
2025年司美格鲁肽原料药竞争格局
药事纵横 · 11-30
2025年司美格鲁肽原料药竞争格局
智通港股空仓持单统计|11月28日
智通财经 · 11-28
智通港股空仓持单统计|11月28日
加载更多
公司概况
公司名称:
凯莱英
所属市场:
SEHK
上市日期:
--
主营业务:
凯莱英医药集团(天津)股份有限公司是一家主要从事提供医药外包一站式综合服务的中国公司。该公司的业务包括小分子药物定制研发生产(CDMO)、化学大分子CDMO、临床研究服务、制剂CDMO、生物大分子CDMO、技术输出和合成生物技术。该公司的产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。该公司主要在国内外市场开展其业务。
发行价格:
--
{"stockData":{"symbol":"06821","market":"HK","secType":"STK","nameCN":"凯莱英","latestPrice":76.9,"timestamp":1766113773424,"preClose":72.45,"halted":0,"volume":161900,"delay":0,"floatShares":27553260,"shares":361000000,"eps":2.9747673848595904,"marketStatus":"交易中","change":4.45,"latestTime":"12-19 11:10:07","open":72.7,"high":77,"low":72.7,"amount":12249692,"amplitude":0.059351,"askPrice":76.9,"askSize":500,"bidPrice":76.75,"bidSize":500,"shortable":3,"etf":0,"ttmEps":3.164546485398819,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1766116800000},"marketStatusCode":2,"adr":0,"listingDate":1639065600000,"exchange":"SEHK","adjPreClose":72.45,"dividendRate":0.015629,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":3.480133,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":95.27,"timestamp":1766113806000,"preClose":91.03,"halted":0,"volume":4266000,"delay":0,"premium":"-27.01"}},"requestUrl":"/m/hq/s/06821","defaultTab":"news","newsList":[{"id":"2592139047","title":"医药外包概念普遍走高 药明生物(02269)涨6.11% 机构看好看好CXO在业绩和估值端迎来双重修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139047","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139047?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:26","pubTimestamp":1766111188,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念普遍走高,药明生物 涨6.11%,凯莱英升5.52%,康龙化成升4.69%,泰格医药升3.8%,维亚生物升3.72%,药明康德涨3.32%。世纪证券此前研报指出,本周NDAA法案落地,地缘风险趋于缓和。CXO业绩和新增订单开始好转,本周市场开始关注临床前安评试验资产食蟹猴。该机构认为CXO作为创新药产业链上游,行业经历过完整周期,有望受益于国产创新药竞争力提升带来的景气度回升,看好CXO在业绩和估值端迎来双重修复。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516422952.EUR","LU0516422366.SGD","LU0348825331.USD","BK1521","BK1574","BK1161","IE00B0JY6N72.USD","LU0039217434.USD","BK1583","LU0819121731.USD","LU0979878070.USD","02359","LU0456827905.SGD","LU1794554557.SGD","LU2045819591.USD","LU1720050803.USD","02269","LU0052750758.USD","LU3063872942.SGD","LU0359201612.USD","01873","09939","LU0043850808.USD","BK1610","159938","LU1046422090.SGD","LU0051755006.USD","03347","06821","LU0320764599.SGD","CXO","LU1880383366.USD","SG9999002463.SGD","BK1589","LU2242644610.SGD","BK1576","LU0516422440.USD","LU2125910500.SGD","LU0140636845.USD","LU0417516902.SGD","LU0516423174.USD","LU0823426480.USD","SG9999002562.SGD","LU1242518931.SGD","LU0708995583.HKD","LU0516423091.SGD","03759","LU0348735423.USD","BK1191","LU0181495838.USD"],"gpt_icon":0},{"id":"2592949186","title":"每日卖空追踪 | 凯莱英 12月17日卖空量成交1200股,卖空比例为0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592949186","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592949186?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:30","pubTimestamp":1765960236,"startTime":"0","endTime":"0","summary":"凯莱英北京时间12月17日,跌0.89%,卖空量成交1200股,较上一交易日减少65.71%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163618a4561504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163618a4561504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06821","BK1191"],"gpt_icon":0},{"id":"2591402946","title":"每日卖空追踪 | 凯莱英 12月15日卖空量成交1900股,卖空比例为1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591402946","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591402946?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787436,"startTime":"0","endTime":"0","summary":"凯莱英北京时间12月15日,跌3.37%,卖空量成交1900股,较上一交易日减少63.46%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163623a44d434f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163623a44d434f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06821","BK1191"],"gpt_icon":0},{"id":"2591657917","title":"医药行业周报:IN VIVO CART:BD热门赛道 早期技术具备广阔前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657917","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591657917?lang=zh_cn&edition=full","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"核心观点:In Vivo CART赛道发展火热,2025年已经有四个MNC并购的案例发生。具体来看,In Vivo CART分为LNP和慢病毒两条技术路线,两条技术路线均具备显著特色。LNP路线来看,药物在临床前展现出了快速转染以及优异的靶向性特点,慢病毒路线中,Esobiotec等公司的BCMA In Vivo CART已经在小人群MM患者中展现非常好的早期数据。整体看,In VivoCART发展迅速,后续发展值得关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214150229a4496027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214150229a4496027&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046422090.SGD","LU2242644610.SGD","BK1161","06821","01801","01177","BK1141","BK1574","BK1576","LU0708995583.HKD","BK1583","LU0052750758.USD","06160","LU2125910500.SGD","LU0320764599.SGD","02359","06978","LU2045819591.USD"],"gpt_icon":0},{"id":"2591632904","title":"英伟达连续布局13家企业,AI制药3个方向梳理(附列表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591632904","media":"投研大叔","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591632904?lang=zh_cn&edition=full","pubTime":"2025-12-13 19:40","pubTimestamp":1765626014,"startTime":"0","endTime":"0","summary":"今天介绍下AI制药,英伟达在过去2年投资13家AI药企,推出BioNeMo生物分子AI框架已经覆盖上百家药企,英硅智能ISM001-055进入临床III期,成为首个跨越临床II期的AI药物,从之前的布局到如今逐渐突破,商业价值正在逐渐被验证。从大叔个人来看,还有一些罕见病,由于患者少,研发不划算,而AI能快速低成本设计药物,让更多罕见病有药可治。近期热门文章HW组建医疗卫生军团,AI医疗爆发!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1280957306.USD","01093","NVD","SGXZ81514606.USD","LU1988902786.USD","IE00BJJMRY28.SGD","LU2191332357.HKD","NVDD","NVDA","02228","LU2089284900.SGD","LU2592432038.USD","LU0719512351.SGD","LU0444973449.USD","IE00BDCRKT87.USD","LU2249611893.SGD","LU0157215616.USD","LU1145028129.USD","LU2420271590.USD","NVIW.SI","LU2065171311.SGD","NVD2.UK","NVDS.UK","03759","LU0096362180.USD","02196","IE000YTNTUN2.SGD","06127","IE000ITXATA3.USD","LU1496350171.SGD","LU2237438978.USD","2NVD.UK","02359","SNVD.UK","LU2602419157.SGD","LU0274383776.USD","NVD3.UK","NVDS","LU1839511570.USD","LU2505996681.GBP","LU2473716301.USD","LU2463028550.USD","LU1642822529.SGD","3NVD.UK","LU1914381329.SGD","LU0158827948.USD","SG9999004303.SGD","LU2505996509.AUD","IE0034235188.USD","NVDY","06821","NVDX","LU2860962120.EUR","LU0308772762.SGD","LU0320765059.SGD","NVDU"],"gpt_icon":1},{"id":"2590850782","title":"每日卖空追踪 | 凯莱英 12月12日卖空量成交3800股,卖空比例为1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590850782","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590850782?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528234,"startTime":"0","endTime":"0","summary":"凯莱英北京时间12月12日,涨0.85%,卖空量成交3800股,较上一交易日减少70.54%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165432979e98c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165432979e98c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06821","BK1191"],"gpt_icon":0},{"id":"2590592453","title":"诺华领跑,药明康德狂飙!小核酸药物市场井喷,中国CDMO产业链迎来爆发式增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2590592453","media":"摩熵医药","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590592453?lang=zh_cn&edition=full","pubTime":"2025-12-11 10:26","pubTimestamp":1765419964,"startTime":"0","endTime":"0","summary":"2016年后,多款重磅小核酸药物陆续上市,在遗传罕见病和慢性病等领域取得重大突破,全球小核酸药物市场进入高速增长通道。近年来,中国小核酸领域的BD交易异常活跃。根据2025年中期报告,包含寡核苷酸、多肽等在内的化学大分子CDMO业务板块,收入达3.79亿元,同比增速超过130%。随着小核酸药物商业化的加速,国内CDMO企业迎来确定性的增长机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211102610a4414f91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211102610a4414f91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","06821","LU0052750758.USD","02359","LU1046422090.SGD","LU2045819591.USD","LU2242644610.SGD","LU2125910500.SGD","BK1576","BK1191","LU0708995583.HKD","LU0320764599.SGD","BK1141"],"gpt_icon":1},{"id":"2590303708","title":"重磅事件落地!商业化+出海提速,板块调整后弹性更突出","url":"https://stock-news.laohu8.com/highlight/detail?id=2590303708","media":"浙商证券融资融券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590303708?lang=zh_cn&edition=full","pubTime":"2025-12-10 13:02","pubTimestamp":1765342962,"startTime":"0","endTime":"0","summary":"关注研发实力强且已有商业化创新药产品上市的企业;CXO及生命科学上游产业链。CXO一体化龙头公司如药明康德,保持业绩持续向好趋势,业绩保持较快增长。投资者据此操作,风险自负。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512101335329534f1c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512101335329534f1c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","BK1583","LU2242644610.SGD","BK1576","LU2125910500.SGD","02268","06160","06978","BK1141","LU0052750758.USD","03759","06821","LU0320764599.SGD","BK1574","02359","LU1046422090.SGD","LU2045819591.USD","BK1161","LU0708995583.HKD"],"gpt_icon":0},{"id":"2590309788","title":"每日卖空追踪 | 凯莱英 12月09日卖空量成交6900股,卖空比例为2.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590309788","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590309788?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269036,"startTime":"0","endTime":"0","summary":"凯莱英北京时间12月09日,跌0.44%,卖空量成交6900股,较上一交易日减少80.83%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163607a43d412e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163607a43d412e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06821"],"gpt_icon":0},{"id":"2589233996","title":"ADC药物浪潮下,凯莱英、药明合联等CDMO企业产能角逐正酣","url":"https://stock-news.laohu8.com/highlight/detail?id=2589233996","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589233996?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:31","pubTimestamp":1765182717,"startTime":"0","endTime":"0","summary":"据悉,药明合联无锡基地目前抗体及偶联原液产能总产能约1.1万升,制剂总产能将计划在2027年扩展至3500万瓶。皓元医药ADC原液年产能可达1500kg,重庆抗体偶联CDMO基地配备1条抗体蛋白原液产线,年设计产能12万升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163650979615fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163650979615fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU2488822045.USD","BK1141","02268","SG9999014674.SGD","06821"],"gpt_icon":0},{"id":"2589354886","title":"每日卖空追踪 | 凯莱英 12月08日卖空量成交1.13万股,卖空比例为2.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354886","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589354886?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:30","pubTimestamp":1765182635,"startTime":"0","endTime":"0","summary":"凯莱英北京时间12月08日,涨0.96%,卖空量成交1.13万股,较上一交易日减少25.17%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163601a72ab03e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163601a72ab03e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06821"],"gpt_icon":0},{"id":"2589339958","title":"凯莱英12月08日主力净流入488.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2589339958","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589339958?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:16","pubTimestamp":1765181761,"startTime":"0","endTime":"0","summary":"12月08日, 凯莱英股价涨0.96%,报收78.80元,成交金额3029.1万元,换手率1.38%,振幅5.57%,量比3.15。凯莱英今日主力资金净流入488.6万元,上一交易日主力净流出0万元。该股近5个交易日下跌2.48%,主力资金累计净流入446.8万元;近20日主力资金累计净流出442.9万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208162232a72aa7a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208162232a72aa7a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06821","BK1191"],"gpt_icon":0},{"id":"2589383288","title":"港股异动 | 凯莱英(06821)午前涨近3% 近期凯莱英生物上海奉贤基地正式投产 重点布局联药物NDCs等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2589383288","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589383288?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:34","pubTimestamp":1765164854,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,凯莱英午前涨近3%,截至发稿,涨2.05%,报79.65港元,成交额1551.75万港元。消息面上,近期,据凯莱英官微消息,公司旗下凯莱英生物的上海奉贤商业化生产基地正式投产,该基地是凯莱英生物继上海金山基地和张江科学技术中心后重点打造的又一核心商业化产业基地,可助力客户快速推进商业化生产。奉贤基地商业化投产意味着凯莱英生物在生物药CDMO领域实现跨越式升级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","002821","BK0239","06821","BK1191","LU1328615791.USD"],"gpt_icon":0},{"id":"2589831268","title":"每日卖空追踪 | 凯莱英 12月04日卖空量成交300股,卖空比例为0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589831268","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589831268?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837037,"startTime":"0","endTime":"0","summary":"凯莱英北京时间12月04日,涨1.44%,卖空量成交300股,较上一交易日减少94.34%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163628952a7cc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163628952a7cc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06821","BK1191"],"gpt_icon":0},{"id":"2589857879","title":"凯莱英12月04日主力净流入71.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2589857879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589857879?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:16","pubTimestamp":1764836167,"startTime":"0","endTime":"0","summary":"12月04日, 凯莱英股价涨1.44%,报收77.65元,成交金额1465.3万元,换手率0.69%,振幅3.79%,量比1.85。凯莱英今日主力资金净流入71.1万元,上一交易日主力净流出0万元。该股近5个交易日下跌1.28%,主力资金累计净流出41.8万元;近20日主力资金累计净流出1137.8万元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204162333978f8192&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204162333978f8192&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06821"],"gpt_icon":0},{"id":"2588070114","title":"每日卖空追踪 | 凯莱英 12月03日卖空量成交1200股,卖空比例为1.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588070114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588070114?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:30","pubTimestamp":1764750633,"startTime":"0","endTime":"0","summary":"凯莱英北京时间12月03日,跌1.73%,卖空量成交1200股,较上一交易日减少67.57%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203163610a4c9f0e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203163610a4c9f0e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06821"],"gpt_icon":0},{"id":"2588028059","title":"凯莱英(002821)披露A股股权激励股份转让进展,12月2日股价下跌2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588028059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588028059?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:24","pubTimestamp":1764685492,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘,凯莱英报收于92.6元,较前一交易日下跌2.06%,最新总市值为333.91亿元。公司近日发布公告称,截至2025年11月30日的证券变动月报表显示,凯莱英A股已发行股份增加291,400股,库存股相应减少291,400股,变动原因为2025年A股股权激励计划项下的库存股份转让。H股和A股的法定/注册股本均无变动,H股限制性股票计划下可能转让的股份为1,465,000股,H股库存股数量未发生变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399300","BK0132","BK1191","LU1328615791.USD","06821","BK0239","002821","159982"],"gpt_icon":0},{"id":"2588828820","title":"行业回暖!盘点2025年CXO订单最高的10家公司:药明系领跑,凯莱英、泰格医药等巨头订单激增","url":"https://stock-news.laohu8.com/highlight/detail?id=2588828820","media":"摩熵医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588828820?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:01","pubTimestamp":1764644506,"startTime":"0","endTime":"0","summary":"2025年,全球CXO行业在逐步回暖,市场需求结构性分化愈发明显。2025前三季度实现营业收入328.57亿元,同比增长18.61%;归属于上市公司股东净利润120.76亿元,同比大增84.84%。截至2025 年9月末,TIDES 在手订单同比增长 17.1%。药明生物截至2025年6月30日收益同比增长16.1%,达人民币99.53亿元。凯莱英、康龙化成、泰格医药及方达控股凯莱英截止2025年Q3总营收达46.3亿,同比增长11.82%。方达控股截止2025年6月30日营收1.27亿,同比下滑1.48%,净利润292.7万,同比增长2600%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202110317a71e24b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202110317a71e24b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03759","06821","SG9999014674.SGD","03347","02268","BK1576","BK1191","LU2488822045.USD","BK1141"],"gpt_icon":0},{"id":"2587798947","title":"2025年司美格鲁肽原料药竞争格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2587798947","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587798947?lang=zh_cn&edition=full","pubTime":"2025-11-30 08:03","pubTimestamp":1764461017,"startTime":"0","endTime":"0","summary":"图:国家药品监督管理局进入2025年,随着多条产线陆续投产与扩产计划落地,我国司美格鲁肽原料药产能正迎来集中释放期。本文将系统梳理当前国内主要企业的现有产能、扩建进展及未来规划,全景呈现2025年司美格鲁肽原料药的产能格局。瀚宇药业计划在2025年将司美格鲁肽原料药产能提升至5-10吨/年,是目前规划最为激进的企业之一。总 结总体来看,国内司美格鲁肽原料药的产能布局已然铺开,这场围绕GLP-1赛道的投入无疑是坚决的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251130080702a4c2ca18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251130080702a4c2ca18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06821","BK1191","02359"],"gpt_icon":0},{"id":"2586785109","title":"智通港股空仓持单统计|11月28日","url":"https://stock-news.laohu8.com/highlight/detail?id=2586785109","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586785109?lang=zh_cn&edition=full","pubTime":"2025-11-28 18:30","pubTimestamp":1764325805,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,截止11月21日,未平仓空单比位列前三位为万科企业、中远海控、恒瑞医药,空仓比分别为19.60%、16.49%、16.36%。未平仓空单比(绝对值)较上一次增加最多为中环新能源、万科企业、东方电气,分别增加2.58%、1.92%、1.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNVGY","03800","LU1303224171.USD","LU1807302812.USD","01735","LU0650527681.SGD","LU1770034418.SGD","00992","PAImain","LU0880133367.SGD","01276","06680","02359","01951","601318","03145","82318","PNGAY","02202","01635","00763","02228","01072","03888","09696","06821","06613","80992","02318","LU0588545490.SGD","02899","BK1507","01428","02382","LU0348805143.USD","HPAD.SI","01919","IE00BZ08YT58.USD","LU1794554557.SGD","000002","LU0287142896.SGD","02498","01910","LU0630378692.HKD","03759","LU0561508036.HKD","LU0918141887.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.asymchem.com","stockEarnings":[{"period":"1week","weight":-0.0542},{"period":"1month","weight":-0.087},{"period":"3month","weight":-0.2663},{"period":"6month","weight":0.052},{"period":"1year","weight":0.4188},{"period":"ytd","weight":0.4312}],"compareEarnings":[{"period":"1week","weight":-0.0013},{"period":"1month","weight":-0.0167},{"period":"3month","weight":-0.0394},{"period":"6month","weight":0.0836},{"period":"1year","weight":0.2836},{"period":"ytd","weight":0.2711}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"凯莱英医药集团(天津)股份有限公司是一家主要从事提供医药外包一站式综合服务的中国公司。该公司的业务包括小分子药物定制研发生产(CDMO)、化学大分子CDMO、临床研究服务、制剂CDMO、生物大分子CDMO、技术输出和合成生物技术。该公司的产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。该公司主要在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.109047},{"month":2,"riseRate":0.5,"avgChangeRate":0.017674},{"month":3,"riseRate":0.25,"avgChangeRate":-0.034311},{"month":4,"riseRate":0.5,"avgChangeRate":-0.084779},{"month":5,"riseRate":0.5,"avgChangeRate":0.040294},{"month":6,"riseRate":0.5,"avgChangeRate":0.01751},{"month":7,"riseRate":0.5,"avgChangeRate":0.064856},{"month":8,"riseRate":0.25,"avgChangeRate":-0.064097},{"month":9,"riseRate":0.75,"avgChangeRate":0.16322},{"month":10,"riseRate":0,"avgChangeRate":-0.125554},{"month":11,"riseRate":0.5,"avgChangeRate":0.010602},{"month":12,"riseRate":0.25,"avgChangeRate":-0.006246}],"exchange":"SEHK","name":"凯莱英","nameEN":"ASYMCHEM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,06821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}